PR Newswire
LOS ANGELES, Nov. 20, 2026
Complaint alleges CVRx, Inc. misled investors between July 25, 2023 and August 6, 2026; investors may seek lead plaintiff role by January 8, 2027
LOS ANGELES, Nov. 20, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX) securities between July 25, 2023 and August 6, 2026. The CVRx, Inc. case, Oklahoma Police Pension and Retirement System v. CVRx, Inc. et al., was filed on November 9, 2026 in the U.S. District Court District of Minnesota (Case No. 0:26-cv-04746).
Investors who suffered losses on CVRx, Inc. investments can submit their CVRx, Inc. loss information here before the January 8, 2027 lead plaintiff deadline.
Key dates in the CVRx, Inc. case
What happened?
On August 6, 2026, after the market close, CVRx filed a Form 10-Q with the SEC disclosing that on May 14, 2026, the Company "received a civil investigative demand from the U.S. Department of Justice in connection with an investigation under the False Claims Act." The Company stated that the "CID requested information and documents regarding an investigation into whether [CVRx] caused the submission of false claims to government health insurance programs by improperly marketing [its] device, offering or paying kickbacks to healthcare providers or providing false information to government health insurance programs."
On this news, CVRx stock fell $3.55, or 59.76%, to close at $2.39 on August 7, 2026, thereby injuring investors.
What is the CVRx, Inc. lawsuit about?
The CVRx, Inc. securities lawsuit alleges that, between July 25, 2023 and August 6, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about CVRx, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) to induce sales growth, CVRx and/or its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act and Anti-Kickback Statute; (2) CVRx's revenues were in part the product of such unlawful conduct and thus unsustainable; (3) the illegal sales and marketing activities increased the risk of criminal and civil liability; and (4) as a result, defendants' positive statements about CVRx, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The complaint against CVRx, Inc. alleges, among other things, that the Company failed to disclose that to induce sales growth, CVRx and/or its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act and Anti-Kickback Statute. For investors who purchased during the class period, the January 8, 2027 lead plaintiff deadline is the first significant deadline to keep in mind," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist CVRx, Inc. investors in potentially pursuing claims to recover their losses.
If you wish to serve as lead plaintiff in the CVRx, Inc. class action, you must move the Court no later than January 8, 2027. To learn more about your rights, visit the CVRx, Inc. case page, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).
You may retain counsel of your choice. If you bought CVRx, Inc. securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the CVRx, Inc. case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired CVRx, Inc. securities between July 25, 2023 and August 6, 2026 and suffered losses may be members of the proposed class in the CVRx, Inc. shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by January 8, 2027.
What is a lead plaintiff? In the CVRx, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Do I have to be lead plaintiff to recover? No. A CVRx, Inc. investor's ability to share in any future recovery does not depend on serving as lead plaintiff. CVRx, Inc. investors may take no action and remain absent class members.
What is the deadline? Motions to serve as lead plaintiff in the CVRx, Inc. class action must be filed by January 8, 2027.
Does it cost anything to contact Glancy or participate in this action? Glancy represents CVRx, Inc. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.
Can I choose my own lawyer? Yes. CVRx, Inc. investors may retain counsel of their choice.
Why work with Glancy on the CVRx, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the CVRx, Inc. lawsuit. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
Contact
Charles H. Linehan
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 | Toll-free: 888-773-9224
www.glancylaw.com
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:https://www.prnewswire.com/news-releases/whats-next-for-cvrx-inc-shareholders-after-59-76-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302946361.html
SOURCE Glancy Prongay Wolke & Rotter LLP
